MED17

Across TCGA pan-cancer cohorts, MED17 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of MED17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MED17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MED17 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, KIRC, and LUAD are the cancer types where MED17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MED17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.676	<.001	11	view →
KIRC	Female	All	+0.619	<.001	11	view →
LUAD	Male	II,III,IV	+0.726	<.001	10	view →
LIHC	Male	II,III,IV	+0.698	<.001	9	view →
COAD	Male	All	+0.564	<.001	9	view →
STAD	Male	II,III,IV	+0.870	<.001	8	view →
KICH	Female	All	−0.814	<.001	7	view →
CHOL	Female	All	+1.816	<.001	5	view →
KIRP	All	IV	+0.810	<.001	4	view →
LUSC	Male	All	+0.345	<.001	4	view →
ESCA	All	All	+0.617	.013	2	view →
READ	All	All	+0.533	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

MED17–HNSC

Open the HNSC breakdown →